Pituitary enlargement following ipilimumab without long term endocrine dysfunction

Hanaizi, 2012, Eur J Cancer, 48, 237, 10.1016/j.ejca.2011.09.018 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Motzer, 2018, Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma, New England J Med, 378, 1277, 10.1056/NEJMoa1712126 Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750 Faje, 2014, Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma, J Clin Endocrinol Metab, 10.1210/jc.2014-2306 Lam, 2015, Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series, Internal Med J, 45, 1066, 10.1111/imj.12819 Ryder, 2014, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr Relat Cancer, 21, 371, 10.1530/ERC-13-0499 Bertrand, 2015, Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, BMC Med, 13, 211, 10.1186/s12916-015-0455-8 Tarhini, 2013, Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management, Scientifica (Cairo), 2013 Carpenter, 2009, Ipilimumab-induced hypophysitis: MR imaging findings, AJNR Am J Neuroradiol, 30, 1751, 10.3174/ajnr.A1623 Rodrigues, 2014, Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions, Endocrinol, Diabetes & Metabolism Case Rep, 2014 Carpenter, 2009, Ipilimumab-induced hypophysitis: MR imaging findings, AJNR Am J Neuroradiol, 30, 1751, 10.3174/ajnr.A1623 Albarel, 2015, Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma, Eur J Endocrinol, 172, 195, 10.1530/EJE-14-0845 Min, 2015, Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study, Clin Cancer Res, 21, 749, 10.1158/1078-0432.CCR-14-2353 Erra, 2019, A rare case of ipilimumab-induced reversible hypophysitis and permanent primary hypothyroidism, Cureus, 11, e5001 Gubbi, 2018, Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions, Rev Endocr Metab Disord, 19, 335, 10.1007/s11154-018-9480-1 Albarel, 2015, Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma, Eur J Endocrinol, 172, 195, 10.1530/EJE-14-0845 Snyders, 2019, Ipilimumab-induced hypophysitis, a single academic center experience, Pituitary, 22, 488, 10.1007/s11102-019-00978-4